United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - ergotamine tartrate; cyclizine hydrochloride; caffeine hydrate - oral tablet - 2mg ; 50mg ; 100mg

United States - English - NLM (National Library of Medicine)

it3 medical llc - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) - dihydroergotamine mesylate injection, usp is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. there have been a few reports of serious adverse events associated with the coadministration of dihydroergotamine and potent cyp 3a4 inhibitors, such as protease inhibitors and macrolide antibiotics, resulting in vasospasm that led to cerebral ischemia and/or ischemia of the extremities. the use of potent cyp 3a4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) with dihydroergotamine is, therefore contraindicated (see warnings: cyp 3a4 inhibitors) dihydroergotamine mesylate injection, usp should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have clinical symptoms or findings consistent with coronary artery vasospasm including prinzmetal's variant angina. (see

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amdipharm ltd. - ergotamine tartrate 1 mg; caffeine 100 mg - tablet - 1 mg - 100 mg - ergotamine tartrate 1 mg; caffeine 100 mg - ergotamine, combinations excl. psycholeptics; n02ca72 ergotamine, combinations with psycholeptics

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amdipharm ltd. - dihydroergotamine mesilate 4 mg/ml - nasal spray, solution - 4 mg/ml - dihydroergotamine mesilate 4 mg/ml - dihydroergotamine

United States - English - NLM (National Library of Medicine)

hikma farmaceutica - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) -

Canada - English - Health Canada

novartis pharmaceuticals canada inc - ergotamine tartrate; caffeine - tablet - 1mg; 100mg - ergotamine tartrate 1mg; caffeine 100mg - sympatholytic (adrenergic blocking) agents

Canada - English - Health Canada

novartis pharmaceuticals canada inc - ergotamine tartrate; caffeine - suppository - 2mg; 100mg - ergotamine tartrate 2mg; caffeine 100mg - sympatholytic (adrenergic blocking) agents

United States - English - NLM (National Library of Medicine)

tersera therapeutics, llc - ergotamine tartrate (unii: mru5xh3b48) (ergotamine - unii:pr834q503t) - ergomar® is indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called "histaminic cephalalgia". coadministration of ergotamine with potent cyp 3a4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin and troleandomycin) has been associated with acute ergot toxicity (ergotism) characterized by vasospasm and ischemia of the extremities (see precautions: drug interactions ), with some cases resulting in amputation. there have been rare reports of cerebral ischemia in patients on protease inhibitor therapy when ergotamine was coadministered, at least one resulting in death. because of the increased risk for ergotism and other serious vasospastic adverse events, ergotamine use is contraindicated with these drugs and other potent inhibitors of cyp 3a4 (e.g., ketoconazole, itraconazole) (see warnings: cyp 3a4 inhibitors ). ergomar® sublingual tablets may cause fetal harm when administered to pregnant women. ergomar® subli

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

a. menarini singapore pte. ltd. - ergotamine tartrate; caffeine -

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amdipharm ltd. - caffeine 100 mg; ergotamine tartrate 2 mg - suppository - 2 mg - 100 mg - ergotamine tartrate 2 mg; caffeine 100 mg - ergotamine, combinations excl. psycholeptics; n02ca72 ergotamine, combinations with psycholeptics